Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure

Journal of the American College of Cardiology

Volumn 69, Issue 7, 2017, Pages 805-819

  Basu, Ratnadeep ^a   Poglitsch, Marko ^b   Yogasundaram, Haran ^a   Thomas, Jissy ^a   Rowe, Brian H ^a   Oudit, Gavin Y ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Attoquant Diagnostics GmbH   (Austria)

Author keywords

angiotensin II; angiotensin (1 7); chymase; dilated cardiomyopathy; renin angiotensin system

Indexed keywords

ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-10]; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-9]; ANGIOTENSIN[2-10]; ANGIOTENSIN[2-7]; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; RECOMBINANT ANGIOTENSIN CONVERTING ENZYME 2; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ADULT; AGED; ANGIOTENSIN BLOOD LEVEL; ARTICLE; CARDIAC MUSCLE; COHORT ANALYSIS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; EX VIVO STUDY; FEMALE; HEART FAILURE; HUMAN; HUMAN TISSUE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ACUTE DISEASE; BLOOD; CASE CONTROL STUDY; CHRONIC DISEASE; COMPLICATION; MIDDLE AGED; PHYSIOLOGY; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED;

EID: 85012977960     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.11.064     Document Type: Article

References (43)

1. 1 Levy, D., Kenchaiah, S., Larson, M.G., et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347 (2002), 1397–1402.
2. 2 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131 (2015), e29–e322.
3. 3 Braunwald, E., Biomarkers in heart failure. N Engl J Med 358 (2008), 2148–2159.
4. 4 Swedberg, K., Eneroth, P., Kjekshus, J., Wilhelmsen, L., CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82 (1990), 1730–1736.
5. 5 Sakata, Y., Masuyama, T., Yamamoto, K., et al. Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertensive rats: different characteristics from renin angiotensin system-independent hypertrophy. J Am Coll Cardiol 37 (2001), 293–299.
6. 6 The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987), 1429–1435.
7. 7 Flather, M.D., Yusuf, S., Kober, L., et al., ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355 (2000), 1575–1581.
8. 8 Givertz, M.M., Manipulation of the renin-angiotensin system. Circulation 104 (2001), E14–E18.
9. 9 Pfeffer, M.A., Swedberg, K., Granger, C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003), 759–766.
10. 10 Pfeffer, M.A., McMurray, J.J., Velazquez, E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003), 1893–1906.
11. 11 Jorde, U.P., Ennezat, P.V., Lisker, J., et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 101 (2000), 844–846.
12. 12 Petrie, M.C., Padmanabhan, N., McDonald, J.E., Hillier, C., Connell, J.M., McMurray, J.J., Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 37 (2001), 1056–1061.
13. 13 Roig, E., Perez-Villa, F., Morales, M., et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 21 (2000), 53–57.
14. 14 Crackower, M.A., Sarao, R., Oudit, G.Y., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417 (2002), 822–828.
15. 15 Mori, J., Patel, V.B., Abo Alrob, O., et al. Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation. Circ Heart Fail 7 (2014), 327–339.
16. 16 Patel, V.B., Zhong, J.C., Grant, M.B., Oudit, G.Y., Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res 118 (2016), 1313–1326.
17. 17 Zhong, J., Basu, R., Guo, D., et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122 (2010), 717–728.
18. 18 Mercure, C., Yogi, A., Callera, G.E., et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 103 (2008), 1319–1326.
19. 19 Epelman, S., Tang, W.H., Chen, S.Y., Van Lente, F., Francis, G.S., Sen, S., Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 52 (2008), 750–754.
20. 20 Haschke, M., Schuster, M., Poglitsch, M., et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet 52 (2013), 783–792.
21. 21 Putko, B.N., Wang, Z., Lo, J., et al. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology. PLoS One, 9, 2014, e99495.
22. 22 Croghan C, Egeghy P. Methods of Dealing With Values Below the Limit of Detection Using SAS. 2003. Available at: http://analytics.ncsu.edu/sesug/2003/SD08-Croghan.pdf. Accessed July 18, 2016.
23. 23 Keizer, R.J., Jansen, R.S., Rosing, H., et al. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacol Res Perspect, 3, 2015, e00131.
24. 24 van de Wal, R.M., Plokker, H.W., Lok, D.J., et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 106 (2006), 367–372.
25. 25 O'Connor, C.M., Starling, R.C., Hernandez, A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365 (2011), 32–43.
26. 26 Menard, J., Campbell, D.J., Azizi, M., Gonzales, M.F., Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 96 (1997), 3072–3078.
27. 27 ClinicalTrials.gov. The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury. Available at: https://clinicaltrials.Gov/ct2/show/nct01597635. Accessed March 2016.
28. 28 Santos, R.A., Simoes e Silva, A.C., Maric, C., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100 (2003), 8258–8263.
29. 29 Sharp, S., Poglitsch, M., Zilla, P., Davies, N.H., Sturrock, E.D., Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats. J Renin Angiotensin Aldosterone Syst 16 (2015), 1149–1158.
30. 30 Fuchs, S., Xiao, H.D., Hubert, C., et al. Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 51 (2008), 267–274.
31. 31 Rice, G.I., Thomas, D.A., Grant, P.J., Turner, A.J., Hooper, N.M., Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383 (2004), 45–51.
32. 32 Chappell, M.C., Pirro, N.T., Sykes, A., Ferrario, C.M., Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension 31 (1998), 362–367.
33. 33 Shefer, G., Marcus, Y., Knoll, E., et al. Angiotensin 1-7 is a negative modulator of aldosterone secretion in vitro and in vivo. Hypertension 68 (2016), 378–384.
34. 34 McKinney, C.A., Fattah, C., Loughrey, C.M., Milligan, G., Nicklin, S.A., Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodeling. Clin Sci (Lond) 126 (2014), 815–827.
35. 35 Iyer, S.N., Ferrario, C.M., Chappell, M.C., Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31 (1998), 356–361.
36. 36 Wei, C.C., Hase, N., Inoue, Y., et al. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest 120 (2010), 1229–1239.
37. 37 Urata, H., Kinoshita, A., Misono, K.S., Bumpus, F.M., Husain, A., Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265 (1990), 22348–22357.
38. 38 Urata, H., Healy, B., Stewart, R.W., Bumpus, F.M., Husain, A., Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 66 (1990), 883–890.
39. 39 Ahmad, S., Wei, C.C., Tallaj, J., et al. Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. J Am Soc Hypertens 7 (2013), 128–136.
40. 40 Wang, W., Patel, V.B., Parajuli, N., et al. Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease. J Mol Med (Berl) 92 (2014), 847–858.
41. 41 Fielitz, J., Hein, S., Mitrovic, V., et al. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J Am Coll Cardiol 37 (2001), 1443–1449.
42. 42 Marc, Y., Llorens-Cortes, C., The role of the brain renin-angiotensin system in hypertension: implications for new treatment. Prog Neurobiol 95 (2011), 89–103.
43. 43 Hildebrand, D., Merkel, P., Eggers, L.F., Schluter, H., Proteolytic processing of angiotensin-I in human blood plasma. PLoS One, 8, 2013, e64027.